Deutsche Bank Upgrades Ligand Pharma (LGND) to Hold

September 7, 2016 7:20 AM EDT
Get Alerts LGND Hot Sheet
Price: $94.07 -1.14%

Rating Summary:
    8 Buy, 3 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 25 | Down: 28 | New: 8
Trade LGND Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Deutsche Bank upgraded Ligand Pharma (NASDAQ: LGND) from Sell to Hold with a price target of $105.00 (from $110.00). Analyst Gregg Gilbert said he sees more balanced risk/reward.

The analyst explained, "When we lowered our rating on LGND shares from Hold to Sell on 8/5, our call was based primarily on what we saw as challenging risk reward for the stock relative to our price target, which already factored in continued strong growth for key royalty drivers Promacta and Kyprolis, material contribution from Evomela, growth in technology deals (tied to Captisol and other platforms), and some pipeline value for future products. With the stock now trading within 10% of our new target of $105, which we lowered from $110 based on more conservative estimates for Evomela, we are moving back to a Hold rating. Key data points / pipeline events to watch for in the coming months include: 1) monthly sales for Promacta, Kyprolis, and Evomela, 2) sparsentan Phase IIb results for focal segmental glomerulosclerosis in 3Q16, 3) SAGE-547 Phase III results for super-refractory status epilepticus in 1H17, and 4) verubecestat Phase III results for Alzheimer’s disease in mid-2017."

For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.

Shares of Ligand Pharma closed at $108.04 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Upgrades

Related Entities

Deutsche Bank

Add Your Comment